医药塑胶包装：市场占有率分析、产业趋势与统计、成长预测（2026-2031）

预计医药塑胶包装市场将从 2025 年的 657.5 亿美元成长到 2026 年的 698.9 亿美元，预计在 2031 年达到 948.3 亿美元，2026 年至 2031 年的复合年增长率为 6.29%。

生物製药和注射剂市场份额的不断增长、更严格的可追溯性法规以及日益成熟的永续性要求（有利于可回收和生物基聚合物）是推动成长的主要因素。欧盟的《包装和包装废弃物法规》(PPWR)于2025年2月生效，强制要求到2030年实现包装的完全可回收性，并加速材料替代计画的实施。北美市场的需求受惠于《药品供应链安全法案》(DSCSA)将于2025年11月到期，该法案将推动智慧化、可序列化包装形式的发展。亚太地区的製造商正利用监管协调和学名药产量激增的优势，提升该地区的成长前景。中型加工商之间的整合（例如，安姆科以135亿美元收购贝瑞世界）为解决无PFAS配方和循环经济投资问题提供了规模优势。

全球医药塑胶包装市场趋势及展望

生物製药和注射对塑胶包装的需求日益增长

随着生物製药在新核准药物中所占比例不断上升，其易受碱性物质浸出、分层和破损的影响，使得先进聚合物成为首选的初级包装容器。 Gerresheimer 的环烯烃聚合物注射器兼具玻璃般的透明度和优异的抗破损性能，最大限度地减少了昂贵生物製药的损失。预计到 2030 年，全球生物製药市场规模将达到 8,561 亿美元，这将推动对可靠注射剂包装的需求。经过验证的吹灌封容器在九个月内对单株抗体的效力和 pH 值均无漂移，从而扩大了聚合物在无菌应用中的使用范围。疫情期间，管瓶的短缺凸显了供应链风险，并促使企业采取双重采购策略，优先选择具有同等监管核准的塑胶容器。

扩大新兴市场的学名药生产

中国的监管改革，特别是上市核准持有人制度的引入，缩短了核准週期，促进了契约製造合作，并增加了包装需求。北京发布的《2025年指南》包含24项措施，旨在2027年实现中国药物警戒体系的现代化，并为合规包装生产线设定了明确的目标。印度与东协之间的核准计画进一步协调了标准，使加工商能够在多个市场部署单一设计。对价格敏感的学名药也优先考虑成本效益高且在长途出口运输中保持坚固耐用的塑胶。

扩大塑胶废弃物法规（欧盟SUP、EPR等）

《塑胶废弃物法规》(PPWR) 规定，到 2030 年，欧盟销售的所有包装都必须强制回收利用，引入了生产者延伸责任制 (EPR) 费用和再生材料含量标准（PET 食品包装的最低含量为 30%），这将增加企业的资金投入和合规负担。虽然药品包装容器可享有医疗保健豁免，但品牌所有者仍需为回收计画提供资金，重新设计多层复合材料，并在 2026 年前逐步淘汰接触材料中的 PFAS。将于 2028 年推出的统一标誌将需要更改包装设计，而 5% 的材料减量目标将进一步加大对本已较薄的壁厚规格的压力。

细分市场分析

聚丙烯以其优异的耐灭菌性和合规性而闻名，预计到2025年将以30.12%的市场份额继续保持主导地位。然而，生物基和再生塑胶预计将以9.05%的复合年增长率超越现有产品，并在2031年重塑医药塑胶包装市场格局。 Avient公司的MevoPure产品线展现了循环经济与合规性的完美结合，在维持ISO 10993和USP VI认证的同时，也实现了高达120%的碳足迹减少。欧盟的再生材料含量强制要求和美国FDA的染料禁令正在加速对再生原料的需求。 UPM公司推出的木质瓶也证实了富含木质素的化学技术的商业性可行性。

第二代生物聚烯和化学回收PET已达到医药级纯度，无需改造设备即可直接取代。然而，医药级再生材料的供应有限，阻碍了其即时扩大生产规模，并导致价格溢价。大型树脂公司正在其欧洲和北美基地附近扩建产能，以缩短物流运输；而亚洲公司则在寻求出口级再生树脂认证，以满足快速增长的订单。这导致医药塑胶包装市场呈现出平衡：传统聚丙烯（PP）仍占据主导地位，而可再生聚合物则在符合PPWR（塑胶包装回收）和企业净零排放承诺的前提下，谨慎但加速地渗透。

截至2025年，受口服固体製剂的普及推动，瓶装和固态容器将占医药塑胶包装市场26.05%的份额。然而，预填充式注射器和药筒将成为主要的成长动力，由于生物製药、GLP-1注射和居家给药药物的普及，其复合年增长率将达到8.29%。 BD的RFID技术iDFill注射器将注射器和包装整合在一起，可根据《药品安全追踪法案》(DSCSA)的要求提供即时可追溯性。

数位连接、高黏度耐受性和与内建注射器的兼容性，正推动这些容器从普通商品转向高附加价值工程系统。同时，儘管管瓶和安瓿瓶在医院药房仍然必不可少，但剂量范围生物製药正越来越多地转向使用格雷斯海默公司的聚合物EZ-fill智能管瓶，这种小瓶简化了灌装和表面处理工程。条状包装、小袋和软包装正逐渐成为偏远地区药房的邮寄包装选择，因为在这些地区，邮资和缓衝成本使得硬质容器无利可图。

区域分析

到2025年，北美将占据全球医药塑胶包装市场36.05%的份额，这得益于先进的GMP工厂、DSCSA序列化截止日期以及回流激励措施。 FDA的指导意见鼓励采用连续生产和智慧感测器，本地加工商正在将RFID技术嵌入包装壁，并对不含PFAS的薄膜合格。进口树脂关税的征收提高了国内产能运转率，鼓励了对生物基原料的投资，并稳定了易受地缘政治衝击的供应链。

在欧洲，严格的法规与永续性相结合，建构了一个强大且不断发展的市场基础。 《塑胶包装法规》(PPWR) 强制要求可回收性、生产者延伸责任制 (EPR) 收费以及禁用全氟烷基和多氟烷基物质 (PFAS)，从而鼓励重新设计，刺激区域加工商增加研发预算。 《一次性塑胶指令》推广单一材料泡壳薄膜，而国家生态调节计画则鼓励低碳包装形式。北欧和德语区国家正在主导试行回收使用过的吸入器和注射器，为聚丙烯提供了闭合迴路途径。

到2031年，亚太地区医药塑胶包装市场将达到9.76%的最高复合年增长率。中国正根据其2025年行动计画加快推进包装品质审核与ICH Q9标准的对接，同时增加对绿色工厂的投入。印度正在加强药典侦测和数位化溯源，为智慧标籤供应商创造机会。东协核准协议简化了数月的文书流程，使出口商能够在成员国之间运输符合标准的包装。日本的生产者责任延伸制度已扩展至医疗包装领域，促进了PCR级聚丙烯的采购。这些利多因素共同推动了亚太地区开发中国家和成熟市场医药塑胶包装市场的发展。

其他福利：

• Excel格式的市场预测（ME）表
• 3个月的分析师支持

目录

第一章 引言

• 研究假设和市场定义
• 调查范围

第二章调查方法

第三章执行摘要

第四章 市场情势

• 市场概览
• 市场驱动因素
  • 生物製药和注射对塑胶包装材料的需求不断增长
  • 扩大新兴国家的学名药生产
  • 轻且不易碎，这是一项物流优势。
  • 居家医疗和电子商务中单剂量包装的应用
  • 现场BFS和3D列印模具用于个人化医疗
  • 抗菌/智慧聚合物相容包装材料
• 市场限制
  • 不断扩大的塑胶废弃物法规（欧盟SUP、EPR等）
  • 波动性聚合物原料价格
  • 政策转变：从生物玻璃瓶转向COP管瓶
  • 医药级再生树脂供不应求
• 供应链分析
• 监管环境
• 技术展望
• 波特五力分析
  • 供应商的议价能力
  • 买方的议价能力
  • 新进入者的威胁
  • 替代品的威胁
  • 竞争强度
• 评估地缘政治情势

第五章 市场规模与成长预测

• 按原料
  • 聚丙烯（PP）
  • 聚对苯二甲酸乙二醇酯（PET）
  • 高密度聚苯乙烯（HDPE）
  • 低密度聚乙烯（LDPE）
  • 环烯烃聚合物/共聚物（COP/COC）
  • 生物基和再生塑料
• 依产品类型
  • 瓶子和固态容器
  • 管瓶和安瓿
  • 预填充式注射器和药筒
  • 泡壳和条状包装
  • 小袋/条状包装/小袋
  • 瓶盖、瓶塞和封口
  • 点滴袋和软袋
• 按包装类型
  • 难的
  • 柔软的
• 透过药物输送途径
  • 口服
  • 注射剂/可注射剂
  • 眼科/鼻科
  • 局部/经皮
• 最终用户
  • 製药公司
  • 合约研发生产组织（CDMO）
  • 医院和诊所
  • 居家医疗环境
• 按地区
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲和纽西兰
    • 亚太其他地区
  • 中东和非洲
    • 中东
      • 阿拉伯聯合大公国
      • 沙乌地阿拉伯
      • 土耳其
      • 其他中东地区
    • 非洲
      • 南非
      • 奈及利亚
      • 埃及
      • 其他非洲地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区

第六章 竞争情势

• 市场集中度
• 策略趋势
• 市占率分析
• 公司简介
  • Amcor PLC
  • Gerresheimer AG
  • AptarGroup Inc.
  • West Pharmaceutical Services Inc.
  • Klockner Pentaplast Group
  • Comar LLC
  • O.Berk Company LLC
  • Pretium Packaging LLC
  • Drug Plastics and Glass Co. Inc.
  • Gil-Pack Ltd.
  • Alpla Group
  • Silgan Holdings Inc.
  • Placon Corporation
  • Sealed Air Corporation
  • Plastipak Holdings

第七章 市场机会与未来展望

The pharmaceutical plastic packaging market is expected to grow from USD 65.75 billion in 2025 to USD 69.89 billion in 2026 and is forecast to reach USD 94.83 billion by 2031 at 6.29% CAGR over 2026-2031.

Growth rests on the rising share of biologics and injectables, stricter traceability rules, and fast-maturing sustainability mandates that reward recyclable and bio-based polymers. In February 2025 the EU's Packaging and Packaging Waste Regulation (PPWR) entered into force, requiring full recyclability by 2030 and accelerating material substitution programs.North American demand benefits from the Drug Supply Chain Security Act (DSCSA) deadline in November 2025, which pushes smart, serialization-ready formats. Asia-Pacific manufacturers leverage regulatory harmonization and surging generic output, lifting the region's growth prospects. Consolidation among mid-tier converters, exemplified by Amcor's USD 13.5 billion merger with Berry Global, brings scale to tackle PFAS-free formulations and circular-economy investments.

Global Pharmaceutical Plastic Packaging Market Trends and Insights

Growing Demand for Plastic Packs for Biologics and Injectables

Biologics now account for a rising share of new drug approvals, and their sensitivity to alkali leaching, delamination, and breakage positions advanced polymers as preferred primary containers. Cyclic olefin polymer syringes from Gerresheimer combine glass-like transparency with superior break resistance, helping minimize costly biologic losses. The global biopharmaceutical sector is expected to reach USD 856.1 billion by 2030, reinforcing demand for high-integrity parenteral packaging. Validated blow-fill-seal containers show no potency or pH drift for monoclonal antibodies over nine months, broadening polymer uptake in sterile applications. During the pandemic, shortages of glass vials highlighted supply-chain risks, prompting dual-sourcing policies that now favor plastic options with equivalent regulatory acceptance.

Expansion of Generic Drug Production in Emerging Markets

Regulatory reforms in China, notably the Marketing Authorization Holder system, shorten approval cycles and attract contract manufacturing alliances that boost packaging volumes. Beijing's 2025 guidance contains 24 measures to modernize drug oversight by 2027, creating clear targets for compliant packaging lines. India and ASEAN mutual recognition programs further harmonize specifications, letting converters scale a single design across multiple markets. Price-sensitive generics also prioritize cost-efficient plastics that remain robust during long-distance export shipments.

Extended Plastics-Waste Regulation (EU SUP, EPR etc.)

The PPWR obliges all packs sold in the EU to be recyclable by 2030 and introduces EPR fees plus recycled-content thresholds-30% for PET food packs-adding capital and compliance burdens. Healthcare exemptions exist for immediate drug containers, yet brand owners must still fund collection schemes, redesign multilayer laminates, and phase out PFAS in contact materials by 2026. Harmonized symbols due in 2028 compel artwork changes, while the 5% material-reduction target squeezes already lean wall-thickness specs.

Other drivers and restraints analyzed in the detailed report include:

1. Lightweight, Shatter-Proof Logistics Advantage
2. Home-Health and E-Commerce Unit-Dose Adoption
3. Volatile Polymer Feedstock Pricing

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Polypropylene retained leadership with 30.12% of pharmaceutical plastic packaging market share in 2025 thanks to its sterilization tolerance and regulatory familiarity. Yet bio-based and recycled grades are set to outpace all incumbents at 9.05% CAGR, reshaping the pharmaceutical plastic packaging market through 2031. Avient's Mevopur range delivers up to 120% carbon-footprint reduction while keeping ISO 10993 and USP VI credentials, illustrating how circularity and compliance now co-exist. EU recycled-content quotas and the FDA's looming dye phase-out intensify demand for renewable feedstocks. UPM's wood-based bottle launch underscores commercial feasibility of lignin-rich chemistries.

Second-generation bio-polyolefins and chemically recycled PET now reach pharmaceutical purity, unlocking drop-in substitution without retooling. However, limited pharma-grade recyclate supplies restrain immediate scale, creating price premiums. Resin majors ramp capacity near European and North American hubs to shorten logistics, while Asian players eye export-grade r-resin certification to capture surging orders. The pharmaceutical plastic packaging market therefore balances legacy PP dominance with measured yet accelerating penetration of renewable polymers that align with PPWR and corporate net-zero pledges.

Bottles and solid containers captured 26.05% of the pharmaceutical plastic packaging market in 2025 owing to oral solid dosage prevalence. Yet pre-fillable syringes and cartridges headline the growth story, advancing at 8.29% CAGR as biologics, GLP-1 injectables, and home-administered drugs proliferate. BD's RFID-enabled iDFill syringe merges device and pack, supplying real-time traceability that dovetails with DSCSA needs.

Digital connectivity, higher viscosity tolerances, and on-body injector compatibility move these containers from commodity to high-value engineered systems. Conversely, vials and ampoules remain essential for hospital compounding, though dose-banded biologics see a shift to polymer-based EZ-fill Smart vials from Gerresheimer that streamline fill-finish operations. Stick packs, sachets, and pouches gain foothold in tele-pharmacy mailers where postage and cushioning costs punish rigid lines.

The Pharmaceutical Plastic Packaging Market Report is Segmented by Raw Material (Polypropylene, Polyethylene Terephthalate, and More), Product Type (Bottles and Solid Containers, Vials and Ampoules, and More), Packaging Format (Rigid, Flexible), Route of Drug Delivery (Oral, Parenteral/Injectable, and More), End-User (Pharma Manufacturers, Cdmos, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America held 36.05% of the pharmaceutical plastic packaging market in 2025, supported by advanced GMP plants, DSCSA serialization deadlines, and reshoring incentives. FDA guidance endorses continuous manufacturing and smart sensors, pushing local converters to embed RFID in pack walls and qualify PFAS-free films.Tariffs on imported resins raise domestic capacity utilization and spur investment in bio-based feedstocks, stabilizing supply chains vulnerable to geopolitical shocks.

Europe combines regulatory stringency with sustainability leadership, forging a robust yet evolving market base. The PPWR enforces recyclability, EPR fees, and PFAS bans, forcing redesigns that stimulate R&D budgets among regional converters. Single-Use Plastics Directive restrictions encourage mono-material blister films, while national eco-modulation schemes reward low-carbon formats. Nordic and DACH states lead pilot take-back schemes for used inhalers and injectors, offering closed-loop polypropylene pathways.

Asia-Pacific delivers the highest 9.76% CAGR for the pharmaceutical plastic packaging market through 2031. China accelerates under its 2025 action plan, aligning packaging quality audits with ICH Q9 while funding green factories. India tightens pharmacopoeial tests and digital traceability, creating opportunities for smart-label suppliers. ASEAN mutual recognition saves months of dossier work, letting exporters ship compliant packs across member borders. Japanese EPR schemes extend to medical packs, catalyzing PCR-grade PP sourcing. Together, these tailwinds strengthen the pharmaceutical plastic packaging market across developing and mature APAC nations.

1. Amcor PLC
2. Gerresheimer AG
3. AptarGroup Inc.
4. West Pharmaceutical Services Inc.
5. Klockner Pentaplast Group
6. Comar LLC
7. O.Berk Company LLC
8. Pretium Packaging LLC
9. Drug Plastics and Glass Co. Inc.
10. Gil-Pack Ltd.
11. Alpla Group
12. Silgan Holdings Inc.
13. Placon Corporation
14. Sealed Air Corporation
15. Plastipak Holdings

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing demand for plastic packs for biologics and injectables
  • 4.2.2 Expansion of generic drug production in EMs
  • 4.2.3 Lightweight, shatter-proof logistics advantage
  • 4.2.4 Home-health and e-commerce unit-dose adoption
  • 4.2.5 On-site BFS and 3-D printed molds for personalized meds
  • 4.2.6 Antimicrobial / smart-polymer enabled packs
• 4.3 Market Restraints
  • 4.3.1 Extended plastics-waste regulation (EU SUP, EPR etc.)
  • 4.3.2 Volatile polymer feedstock pricing
  • 4.3.3 Biologic-glass policy shift toward COP vials
  • 4.3.4 Scarcity of pharma-grade r-resin supply
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Rivalry
• 4.8 Assessment of Geopolitical Scenario

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Raw Material
  • 5.1.1 Polypropylene (PP)
  • 5.1.2 Polyethylene Terephthalate (PET)
  • 5.1.3 High-Density Polyethylene (HDPE)
  • 5.1.4 Low-Density Polyethylene (LDPE)
  • 5.1.5 Cyclic Olefin Polymer / Copolymer (COP/COC)
  • 5.1.6 Bio-based and Recycled Plastics
• 5.2 By Product Type
  • 5.2.1 Bottles and Solid Containers
  • 5.2.2 Vials and Ampoules
  • 5.2.3 Pre-fillable Syringes and Cartridges
  • 5.2.4 Blister Packs and Strip Packs
  • 5.2.5 Pouches / Stick Packs / Sachets
  • 5.2.6 Closures, Caps and Lids
  • 5.2.7 IV Bags and Flexible Bags
• 5.3 By Packaging Format
  • 5.3.1 Rigid
  • 5.3.2 Flexible
• 5.4 By Route of Drug Delivery
  • 5.4.1 Oral
  • 5.4.2 Parenteral / Injectable
  • 5.4.3 Ophthalmic / Nasal
  • 5.4.4 Topical / Transdermal
• 5.5 By End-User
  • 5.5.1 Pharma Manufacturers
  • 5.5.2 Contract Development and Manufacturing Orgs (CDMOs)
  • 5.5.3 Hospitals and Clinics
  • 5.5.4 Home-care Settings
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Russia
    • 5.6.2.7 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia and New Zealand
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 Middle East
      • 5.6.4.1.1 United Arab Emirates
      • 5.6.4.1.2 Saudi Arabia
      • 5.6.4.1.3 Turkey
      • 5.6.4.1.4 Rest of Middle East
    • 5.6.4.2 Africa
      • 5.6.4.2.1 South Africa
      • 5.6.4.2.2 Nigeria
      • 5.6.4.2.3 Egypt
      • 5.6.4.2.4 Rest of Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes global overview, market level overview, core segments, financials as available, strategic info, market rank/share, products and services, recent developments)
  • 6.4.1 Amcor PLC
  • 6.4.2 Gerresheimer AG
  • 6.4.3 AptarGroup Inc.
  • 6.4.4 West Pharmaceutical Services Inc.
  • 6.4.5 Klockner Pentaplast Group
  • 6.4.6 Comar LLC
  • 6.4.7 O.Berk Company LLC
  • 6.4.8 Pretium Packaging LLC
  • 6.4.9 Drug Plastics and Glass Co. Inc.
  • 6.4.10 Gil-Pack Ltd.
  • 6.4.11 Alpla Group
  • 6.4.12 Silgan Holdings Inc.
  • 6.4.13 Placon Corporation
  • 6.4.14 Sealed Air Corporation
  • 6.4.15 Plastipak Holdings

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-space and Unmet-need Assessment